Nature Technology Receives US Patent for Retro-Vectors.Business Editors/Health/Medical Writers BIOWIRE2K LINCOLN, Neb.--(BUSINESS WIRE)--June 5, 2003 Nature Technology Corporation (NTC NTC Notice NTC National Training Center NTC National Telecommunications Commission NTC National Transport Commission (Australia) NTC Negative Temperature Coefficient NTC Naval Training Center ) today announced US Patent 6,573,091, for a novel type of gene therapy vector (delivery vehicle) that overcomes a key safety problem. While retroviruses are the most widely used vectors for gene therapy, they often carry DNA sequences that lead to genetic recombination, resulting in transfer of virus rather than the therapeutic genes. NTC scientists solved the problem by finding substitute DNA sequences that prevent the recombination events leading to virus production. "The answer lies in the packaging signal, which allows the vector entry into the vector particle," said NTC scientist Clague Hodgson. "Substituting a packaging signal from a mouse VL30 genetic element removed the gene sequences responsible for recombination, without sacrificing efficiency. Overcoming this key safety issue positions the VL30 vector system to have broad utility in gene therapy for the treatment of multiple diseases including cancer and genetic disorders." NTC pioneered the VL30 vector system, based upon retrotransposons (mobile genetic elements Mobile genetic elements (MGE) are a type of DNA that can move around within the genome. They include:
DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. vectors. Additional information can be found at: http://www.natx.com http://www.natx.com/VLVectors.html Related publications: Grunkemeyer, J.A., Hodgson, C.P., Cosgrove, D., (2001) Sustained tissue-specific transgene transgene a gene that has been incorporated into the genome of another organism. expression from a VL30 retrotransposon-derived vector. Gene Ther. Mol. Biol. 6:91-99. http://www.gtmb.org/PDFVolume6/0.8_clague_91-99.pdf Staplin, W.R., Hodgson, C.P., and Knezetic, J.A., (2002) Conserved, erythropoietin-responsive VL30 promoters isolated from erythroid erythroid /er·y·throid/ (er´i-throid) 1. of a red color; reddish. 2. pertaining to the cells of the erythrocytic series. er·y·throid adj. 1. progenitor cells. Blood Cells, Molecules, and Diseases. 28(2): 275-282. Staplin, WR, Knezetic, JA, (2002) BVL-1 like VL30 promoter sustains long-term expression in erythroid progenitor cells. Blood 2003, 101:1798-800 US Patents for VLVector technology:
5,354,674
5,879,933
6,027,722
6,287,863
6,410,220
6,573,091
Link to text of patent: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO PTO abbr. 1. Parent Teacher Organization 2. or p.t.o. please turn over 3. power takeoff PTO or pto please turn over Noun 1. 2&Sect2= HITOFF&p=1&u=/netahtml/search-bool.html&r=1&f=G&l=50&co1=AND&d= ptxt&s1=hodgson.INZZ.&OS=IN/hodgson&RS=IN/hodgson (Due to the length of this URL URL in full Uniform Resource Locator Address of a resource on the Internet. The resource can be any type of file stored on a server, such as a Web page, a text file, a graphics file, or an application program. , it may be necessary to copy and paste To copy files from one location to another or to copy text and images from one document to another. All modern operating systems and applications have a copy and paste capability that is typically selected from an Edit menu. See cut and paste and Win Copy between windows. this hyperlink into your Internet browser's URL address field.) |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion